Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority r
Atos appoints Paul Potgieter as Head of Middle East & Türkiye Paris, France, September 28, 2026 – Atos today announces the appointment of Paul Potgieter as Head of Middle East & Türkiye (MET), reinforcing the company's commitment to accelerating growth and innovation in Artificial Intelligence, Sovereignty and Cybersecurity across the region. Paul Potgieter joins Atos with more than 24 years of international technology leadership experience, having successfully led large-scale business, digital
Press Release Eviden and AllWayTon partner to bring the first triple-mode FRMCS/5G P/GSM-R smartphones to railway industry The solution combines Eviden’s MCX technology with AllWayTon’s railway smartphones to support the transition from aging GSM-R to FRMCS, the next-generation railway communications Paris, France – September 22, 2026 – Eviden, the Atos Group product brand leading in cybersecurity products, mission-critical systems and vision AI today announces an exclusive partnership with AllW
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.